In 2022, the FDA approved the use of T-DXd for unresectable or metastatic HER2-low breast cancer as second-line therapy after chemotherapy or if there was disease recurrence during or within six months of completing adjuvant chemotherapy [17]. This evidence concerns the gene ERBB2 and breast cancer.